Neuro

Colson Medical Announces Hjalmar Pompe van Meerdervoort as New Acumed President

Retrieved on: 
Wednesday, June 1, 2022
Osteomed, LLC, Neuro, Marmon, Tool, Iggie Wolfington, CEO, Medicine, Solution, Zimmer Biomet, Health, Growth, Stryker Corporation, Guangzhou, Patient, Berkshire Hathaway, Injury, General manager, Surgeon, CMF, Education, Management, Dentistry, Apex, Acumed

HILLSBORO, Ore., June 1, 2022 /PRNewswire-PRWeb/ -- Colson Medical, LLC announces Hjalmar Pompe van Meerdervoort as President, Acumed, effective June 1. Pompe van Meerdervoort succeeds Sharon Wolfington, who will transition into a new advisory role for Colson Medical, LLC. After nearly five years at Acumed, Wolfington chose to pursue other professional and personal opportunities.

Key Points: 
  • Colson Medical, LLC announces the appointment of Hjalmar Pompe van Meerdervoort to the role of president, Acumed, effective June 1.
  • HILLSBORO, Ore., June 1, 2022 /PRNewswire-PRWeb/ -- Colson Medical, LLC announces Hjalmar Pompe van Meerdervoort as President, Acumed, effective June 1.
  • Pompe van Meerdervoort succeeds Sharon Wolfington, who will transition into a new advisory role for Colson Medical, LLC.
  • Pompe van Meerdervoort brings extensive global healthcare experience with his more than 25-year career in orthopaedics and medical devices.

Providence St. Jude Medical Center Earns #1 Ranking in California in New Report

Retrieved on: 
Tuesday, May 31, 2022
Joint Commission, Physician, Hospital, UC, Mother, Critical care, Neuro, Patient, UC Davis Medical Center, Providence St. Peter Hospital, Data science, Providence High School, Father, Stroke, Catholic (term), Caregiver, Modern Healthcare, Culture, Stanford University Medical Center, Cedars-Sinai Medical Center, U.S. News & World Report Best Hospitals Rankings, Pulmonary embolism, Sepsis, Orthopedic surgery, Diagnosis, MD, Medicine, Healthgrades

FULLERTON, Calif., May 31, 2022 /PRNewswire/ -- After comparing the clinical performance of California hospitals in treating stroke, Healthgrades—a national leader in healthcare measurement and transparency—ranked Providence St. Jude Medical Center as the state's best performing hospital. 

Key Points: 
  • "We're grateful to be recognized as the best in California," explains Providence St. Jude Chief Executive, Laura Ramos.
  • Like stroke, the critical care top ranking follows three years of being named one ofAmerica's 100 Best Hospitals for Critical Careby Healthgrades.
  • Only four other hospitals in California matched Providence St. Jude's accomplishment of ranking among the top five in multiple areas: Stanford University Medical Center, Cedars Sinai Medical Center, UCLA Santa Monica Medical Center, and UC Davis Medical Center.
  • Providence Southern California is part of Providence , a health system of 111,000 caregivers serving in 51 hospitals, 829 clinics and a comprehensive range of services across Alaska, California, Montana, New Mexico, Oregon, Texas and Washington.

Onera Presents Its Latest Research at SLEEP 2022

Retrieved on: 
Monday, May 30, 2022
Medical Devices, Health, Clinical Trials, Research, Science, Biotechnology, Physician, ONERA, American Academy, American Academy of Sleep Medicine, SRS, Doctor of Philosophy, Charlotte Convention Center, Neuro, Health, Patient, Sleep Research Society, Associated, Quality of life, PSG, Research, FDA, Efficiency, AASM, Wireless, Polysomnography, LLC, Sleep, Pharmaceutical industry

Onera Health, a leader in transforming sleep medicine and remote monitoring, today announced that it will showcase its innovative patch-based polysomnography (PSG) system Onera STS in a late-breaking abstract at SLEEP 2022, the annual meeting of the American Academy of Sleep Medicine (AASM) and the Sleep Research Society (SRS), which is being held from June 4-8 in Charlotte, North Carolina.

Key Points: 
  • Onera Health, a leader in transforming sleep medicine and remote monitoring, today announced that it will showcase its innovative patch-based polysomnography (PSG) system Onera STS in a late-breaking abstract at SLEEP 2022, the annual meeting of the American Academy of Sleep Medicine (AASM) and the Sleep Research Society (SRS), which is being held from June 4-8 in Charlotte, North Carolina.
  • Oneras researcher, Flavio Raschell, PhD, will present the latest data of the ongoing clinical validation studies around the companys recently FDA-cleared Onera STS (Sleep Test System), providing further evidence on efficiency and accuracy of recorded clinical information by Oneras solution in comparison to traditional in-lab PSG testing.
  • Furthermore, Onera will exhibit its ground-breaking solution at SLEEP 2022, Booth #168, at the Charlotte Convention Center.
  • The 36th annual SLEEP meeting of the Associated Professional Sleep Societies, LLC (APSS) is a joint venture of AASM and SRS, bringing together renowned experts whose backgrounds, perspectives and experiences reflect the diversity of the fields of sleep medicine and sleep and circadian research.

Global Oncology Information Systems (Software, Professional Services) Market Size, Share & Trends Analysis Report 2022-2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, May 27, 2022
Software, Technology, Health, Oncology, Brainlab, Cancer, Surgical oncology, Immunotherapy, OIS, Oncology, Neuro, Investment, Government, Solution, Radiation, Co-production (public services), USD, Professional services, HPV, Varian Medical Systems, IBM Watson Health, Chapter Three, Software, Awareness, Watson (computer), Elekta, 3D ultrasound, Correction, Hospital, Product, Cyberknife, Hepatitis, Adoption, Cancer Breakthroughs 2020, CAGR, Globe, Prevalence, Growth, Data management, Medical imaging, Pharmaceutical industry, Medical device, Application

The "Oncology Information Systems Market Size, Share & Trends Analysis Report by Products & Services (Software, Professional Services), by Application (Medical Oncology, Surgical Oncology), by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Oncology Information Systems Market Size, Share & Trends Analysis Report by Products & Services (Software, Professional Services), by Application (Medical Oncology, Surgical Oncology), by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • Increasing investments in the field of oncology by both governments as well as key players is one of the key factors for boosting the market growth.
  • The market growth can be attributed to technological advancements in OIS and the increasing prevalence of cancer on a global level.
  • Chapter 3 Global Oncology Information Systems Market Variables, Trends, & Scope
    Chapter 4 Oncology Information Systems Market: Products & Services Estimates & Trend Analysis
    Chapter 5 Oncology Information Systems Market: application, Estimates & Trend Analysis
    Chapter 6 Oncology Information Systems Market: Regional Estimates & Trend Analysis, by Products and Services, and Application

Pipeline Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference

Retrieved on: 
Thursday, May 26, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Patient, FDA, CNS, IND, Company, LinkedIn, Therapy, Conference, MS, Program, Neuro, CEO, Pharmaceutical industry

Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, announced today that company management will present at the Jefferies Global Healthcare Conference taking place June 8-10, 2022 in New York, NY.

Key Points: 
  • Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, announced today that company management will present at the Jefferies Global Healthcare Conference taking place June 8-10, 2022 in New York, NY.
  • Carmine Stengone, Pipelines President and CEO, will present a company overview on Thursday, June 9, 2022 at 10:00 am ET.
  • Company management will also participate in one-on-one meetings with investors during the conference.
  • Pipeline Therapeutics is a clinical-stage biopharmaceutical company pioneering the development and commercialization of first-in-class therapies for precision neuroregeneration including myelin restoration, synaptogenesis and axonal repair.

ZZ Biotech’s Stroke Drug Moves Closer to Pivotal Phase 3 Clinical Trial as the NIH Awards First Tranche of $30 Million Grant to the Keck School of Medicine of USC

Retrieved on: 
Tuesday, May 24, 2022
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, FDA, Clinical Trials, Physician, Keck School of Medicine of USC, Inflammation, Death, Education, USC, Lists of diseases, Annals of Neurology, Medicine, Incidence, Doctor of Philosophy, National Institute of Neurological Disorders and Stroke, National Institute, Patient, ZZ, Health, APC, Clinical trial, Physiology, Bleeding, Endothelium, Feedback, Neurology, Trial of the century, Phase 3, NIH, Neuron, Neuro, FDA, Brain, Disability, NINDS, University, Neurological disorder, Wound healing, Fast Track, LLC, ALS, Pharmaceutical industry, Neuroscience, Stroke

The remainder of the grant will be funded in subsequent tranches, pending review of milestones over the 6-year grant period.

Key Points: 
  • The remainder of the grant will be funded in subsequent tranches, pending review of milestones over the 6-year grant period.
  • The primary endpoint of the trial is to test 3K3A-APC as a cerebroprotectant, a drug that hastens or augments recovery after stroke.
  • A secondary endpoint will gauge the efficacy of 3K3A-APC at minimizing brain bleeds when combined with two standard treatments for acute ischemic stroke.
  • This will be the second clinical trial of 3K3A-APC in stroke to be supported by grants from NINDS.

Biocept Reports First Quarter 2022 Financial Results

Retrieved on: 
Monday, May 23, 2022
Biotechnology, Health, Oncology, Medical Devices, Cancer, Physician, PIN, Risk, Blood, Private Securities Litigation Reform Act, Research, Public health, U.S. Securities and Exchange Commission, Neuro, Webcast, Investment, Patient, News, Contract, Review, Oncology, COVID-19, Marketing, RT, COVID-19 testing, Medicare, Intention, Cerebrospinal fluid, Forward-looking statement, RT-PCR, Central nervous system, Technology, Terminology, Adoption, LinkedIn, Twitter, SEC, Growth, Target, Security (finance), Annual report, CEO, Online gambling, Pharmaceutical industry, Video game, Facebook

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three months ended March 31, 2022 and provides a business update.

Key Points: 
  • Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three months ended March 31, 2022 and provides a business update.
  • Management plans to resume holding quarterly conference calls concurrent with the reporting of financial results beginning with the second quarter of 2022.
  • Net revenues for the first quarter of 2022 were $19.9 million, a 12% increase from $17.8 million for the first quarter of 2021.
  • Biocept accessioned 153,056 commercial samples during the first quarter of 2022, compared with 141,340 commercial samples during the first quarter of 2021.

GenSight Biologics Announces Publication of a Study of the Impact of LHON Disease on the Lives of Patients and Relatives in Journal of Neuro-Ophthalmology

Retrieved on: 
Thursday, May 19, 2022
Science, Biotechnology, Research, Pharmaceutical, Optical, Health, Genetics, Clinical Trials, Sequence, Work, Sex linkage, Parenting, Guilt, Literature, Participation, Systematic review, University, Moorfields Eye Hospital, National Eye Institute, Incidence, Natural history, Quality of life, Kawasaki, Marketing, Gray platelet syndrome, Research, Optogenetics, Mitochondrial disease, Severe cognitive impairment, Mitochondrion, Department, DNA, Company, Pain, Retina, Doctor of Philosophy, Partner, Patient, REALITY, Eye, Shoulder, Retinal ganglion cell, MTS, VF-14, Disability, MD, BioMed Central, Optic neuropathy, ISIN, Science, University of Cambridge, Neuro, Life, LHON, Union, National Eye, Leber's hereditary optic neuropathy, Mutation, Kawasaki disease, Diagnosis, Cataract, Pharmaceutical industry, Medical device, Medicine, Medical imaging, Phosphorus, Euronext

The study determined that the impact of LHON extends beyond vision-related activity limitations, while addressing its psychosocial impact.

Key Points: 
  • The study determined that the impact of LHON extends beyond vision-related activity limitations, while addressing its psychosocial impact.
  • Additionally, the study determined that despite residing in different countries, LHON patients and their relatives described similar experiences in the four areas of focus in this study.
  • The objective of this study was to comprehensively explore the impact of LHON on the lives of patients and their relatives at the time of diagnosis and now.
  • The Impact of Leber Hereditary Optic Neuropathy on the Quality of Life of Patients and Their Relatives: A Qualitative Study
    1.

iMediSync Leads Global Remote Healthcare Market With Its AI-Based Brain Scanning Device iSyncWave

Retrieved on: 
Friday, May 13, 2022
Technology, Biotechnology, Mobile, Wireless, Health, Other Technology, Mental Health, Research, Medical Devices, Software, Managed Care, Hospitals, Hardware, Science, Data Management, Department, CES, Adolescence, Low-level laser therapy, AI, Neuro, Heart rate variability, Multimedia, Red Dot, PBM, Neuropsychiatry, Insurance, Dementia, Solution, COVID-19, Inspira Health Network, MCI, Electroencephalography, Exercise, Telehealth, Time, EEG, Hospital, Technology, Biomarker, Prognosis, Mental health, Harvard Medical School, Diagnosis, CEO, HRV, Pharmaceutical industry, Neurofeedback

Aligned with this, iSyncWave , an innovative AI-based brain-scanning device, gained global media attention during the event.

Key Points: 
  • Aligned with this, iSyncWave , an innovative AI-based brain-scanning device, gained global media attention during the event.
  • iSyncWave is the worlds first integrated wireless EEG measurement and Neurotherapy convergence solution and is a remote-care mental health platform device.
  • The device is a 100 percent dry-type headset equipped with the age/gender matching normative database with 1,300+ healthy brainwaves covering almost all ages.
  • Also, the device is equipped with PBM (Photobiomodulation) LED therapy to suppress brain cells from dying, which provides personalized therapy protocols that target neuro-related diseases.

Kiromic BioPharma Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

Retrieved on: 
Friday, May 13, 2022
Biotechnology, Technology, Health, Pharmaceutical, Oncology, Other Technology, Research, Software, Genetics, Science, Clinical Trials, Diamond, GDT, DNA, Software, Inc., Company, Immunotherapy, Drug discovery, Goal, NASDAQ, Clinical trial, CGMP, D, Kirom Bukhoroi, Good manufacturing practice, Neuro, Research, RVV, Securities Exchange Act of 1934, Board, Terminology, Technology, Drug development, Machine learning, LinkedIn, Lutheran Student Fellowship, Twitter, CAR, Data mining, SEC, Private Securities Litigation Reform Act, Cancer, Annual report, ALEXIS, Medical device, Mobile phone, Vaccine, Pharmaceutical industry, Gamma delta T cell

This past quarter has seen tremendous progress inside the Company, particularly within the research, development, and manufacturing functions.

Key Points: 
  • This past quarter has seen tremendous progress inside the Company, particularly within the research, development, and manufacturing functions.
  • We have a tremendous opportunity ahead of us, with incredible science that we are looking forward to ultimately making available to patients.
  • Quarter 1 Fiscal Year 2022 Financial Highlights:
    Cash Position: Cash and cash equivalents were $15,123,100 as of March 31, 2022, compared to $25,353,900 as of December 31, 2021.
  • The difference is attributable to cash outflows of $7,520,200, $2,541,800, and $168,800 for operating, investing, and financing activities, respectively.